Keyphrases
Neoadjuvant Chemotherapy
88%
Breast Cancer
50%
HER2+ Breast Cancer
34%
Neoadjuvant Therapy
34%
Neoadjuvant Endocrine Therapy
31%
United States
31%
Survivorship
29%
Overall Survival
28%
Ovarian Suppression
24%
Confidence Interval
23%
Pathological Complete Response
22%
Survival Outcomes
20%
Hormone Receptor-positive
18%
Odds Ratio
18%
Survival Benefit
17%
Breast Reconstruction
17%
Postmenopausal Women
16%
Inflammatory Breast Cancer
15%
Gonadotropin-releasing Hormone
15%
Living with
15%
Diabetes Insipidus
15%
Hypophysitis
15%
Leucocytic
15%
Advanced Breast Cancer
15%
Hematopoietic Cell Transplantation
15%
Myelofibrosis
15%
Acute Myeloid Leukemia
15%
GnRH Analogue
15%
Locally Advanced
15%
Patient Adherence
15%
Patient Preference
15%
Triple-negative Breast Cancer
15%
Immunomodulatory Effect
15%
Hormone Receptor-positive Breast Cancer
15%
Allogeneic Transplant
15%
Node-negative
15%
Disease-free Survival
15%
Invasive Disease
15%
Adjuvant Trastuzumab
15%
Without Chemotherapy
15%
Cancer Survivorship
15%
COVID-19 Pandemic
15%
Extension for Community Healthcare Outcomes
15%
Healthcare Professionals
15%
Survivorship Education
15%
Community Health Care
15%
Axilla
15%
Axillary Management
15%
Real-world Treatment Patterns
15%
Radiation Management
15%
Medicine and Dentistry
Breast Cancer
100%
Neoadjuvant Chemotherapy
86%
Hormone Therapy
46%
Hormone Receptor
34%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
33%
Neoadjuvant Therapy
33%
Overall Survival
29%
Premenopause
18%
Odds Ratio
18%
Body Mass Index
18%
Recurrence Free Survival
17%
Survivorship in Cancer Care
15%
Diabetes Insipidus
15%
Acute Myeloid Leukemia
15%
Inflammatory Breast Cancer
15%
Gonadotropin-Releasing Hormone
15%
Axilla
15%
Hypophysitis
15%
Patient Compliance
15%
Myelofibrosis
15%
Triple Negative Breast Cancer
15%
Patient Preference
15%
COVID-19
15%
Dexamethasone
15%
Cell Transplantation
15%
Gonadorelin Derivative
15%
Adjuvant Endocrine Therapy
15%
Trastuzumab
15%
Hematopoietic Cell
15%
Dietary Pattern
15%
Tamoxifen
12%
Disease Free Survival
11%
Needs Assessment
11%
Oncology
11%
Side Effect
9%
Ovary Function
8%
International Prognostic Scoring System
8%
Diabetes Mellitus
7%
Univariate Analysis
7%
Neoplasm
7%
Clinical Trial
7%
Malignant Neoplasm
6%
Arm
6%
Nurse
6%
Myelodysplastic Syndrome
6%
Radiation Therapy
6%
Hazard Ratio
6%
Logistic Regression Analysis
5%
Tumor Infiltrating Lymphocyte
5%
Sentinel Lymph Node
5%
